Skip to main content
倍益康 logo

倍益康 — Investor Relations & Filings

Ticker · 920199 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 360 across all filing types
Latest filing 2023-04-06 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920199

About 倍益康

https://www.qlbeoka.com/

Beiyikang focuses on the research, development, and manufacturing of rehabilitation and physical therapy equipment. The company integrates professional medical technology with consumer-oriented health solutions. Its product lineup features percussive massage devices, oxygen concentrators, blood pressure monitors, and specialized physical therapy instruments for pain relief and muscle recovery. By utilizing advanced manufacturing processes and technological innovation, Beiyikang delivers products for sports recovery, clinical rehabilitation, and personal health management. The company prioritizes the incorporation of smart technology into its hardware to improve therapeutic outcomes and user experience across its range of recovery and wellness devices.

Recent filings

Filing Released Lang Actions
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company through stock issuance in 2021 and 2022. It includes specifics on fundraising amounts, fund storage, usage, interest income, regulatory approvals, and auditor verification reports. The content focuses on the use of capital raised, compliance with regulations, and includes auditor's attestation on the use of funds. This matches the description of a Capital/Financing Update, which covers updates on company fundraising and capital structure changes. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-04-06 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022年度内部控制自我评价报告' which translates to '2022 Annual Internal Control Self-Evaluation Report'. It is a detailed report on the company's internal control system, its effectiveness, risk assessment, control activities, and internal supervision for the fiscal year ending December 31, 2022. The document includes detailed descriptions of internal control principles, organizational structure, audit committee setup, risk management, and control deficiencies assessment. It is not a general annual report (10-K) but a specialized report focusing on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles. The document is substantive and detailed, not merely an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-06 Chinese
2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as an annual report summary and contains detailed financial data for the year 2022, including assets, liabilities, net profit, earnings per share, and shareholder information. It also includes audit information with a standard unqualified opinion from an accounting firm, details on dividend distribution, company business overview, and notes on asset restrictions. The length of the document (over 10,000 characters) and the presence of substantive financial data and analysis confirm it is a full annual report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K).
2023-04-06 Chinese
第三届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 11th meeting of the 3rd Board of Directors of Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It includes multiple agenda items such as approval of the 2022 General Manager's report, 2022 Board report, 2022 Independent Directors' report, 2022 Audit report, 2022 Annual report and summary, 2022 Financial settlement report, 2023 Financial budget report, 2022 Profit distribution plan, reappointment of the accounting firm, 2023 remuneration plan for directors and senior management, special report on the use of raised funds, special explanation on non-operating fund occupation and related party transactions, governance self-inspection report, internal control self-evaluation report, and the proposal to convene the 2022 Annual General Meeting. The document is a formal board meeting resolution announcement, not the reports themselves, which are referenced as being disclosed separately on the Beijing Stock Exchange information platform. The document is over 6000 characters and contains substantive content about board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. It is not an Annual Report (10-K) or Audit Report (AR) because it does not contain the full reports but only resolutions about them. It is not a Regulatory Filing (RNS) because it is a formal board meeting resolution announcement. Therefore, the correct classification is MANG with high confidence.
2023-04-06 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement about the progress of a share repurchase (buyback) plan by the company Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It includes specifics on the repurchase scheme, pricing, quantity, funding source, and progress as of a certain date. The text does not contain financial statements or quarterly/yearly financial results but focuses on the company's share repurchase activity. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2023-04-02 Chinese
四川千里倍益康医疗科技股份有限公司以自筹资金预先投入募集资金投资项目及支付发行费用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed verification report (鉴证报告) issued by a certified public accounting firm (ShineWing) regarding the use of self-raised funds to pre-invest in projects intended to be funded by raised capital and to pay issuance expenses. It references specific regulatory guidelines from the China Securities Regulatory Commission and the Beijing Stock Exchange, including the '上市公司监管指引第2号' and related listing rules. The report includes detailed financial figures, project investment plans, and the CPA's verification opinion on the accuracy and compliance of the company's disclosures as of November 30, 2022. The document is not a full annual or interim report but a standalone audit/verification report focused on a specific aspect of capital use and compliance. It contains substantive financial data and an auditor's opinion, fitting the definition of an Audit Report / Information (AR). It is not merely an announcement or certification letter, nor is it a general regulatory filing or a report publication announcement. Therefore, the appropriate classification is AR with high confidence.
2023-03-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.